I believe this may be wrong in the PR since it is
Post# of 144918
![](/assets/46931549/no_avatar_available_thumb.jpg)
A new trial in the U.S. may also be why they rolled back the enrollment in Brazil
Quote:
If approved by the FDA, patients in this trial will be randomized in a 1:1 ratio to receive up to four doses of 700 mg leronlimab with standard of care or placebo with standard of care administered by 30-minute IV infusion weekly over a four-week treatment period.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)